Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365408 | 1.00 | TSHR (0.56) | TSHRMAPK1RAB9ANPC1HPGD | |
| SCHEMBL3368700 | 0.90 | HPGD (0.60) | TSHRMAPK1RAB9ANPC1HPGD | |
| SCHEMBL3368692 | 0.90 | HPGD (0.60) | TSHRMAPK1RAB9ANPC1HPGD | |
| SCHEMBL3366093 | 0.89 | ALDH1A1 (0.66) | TSHRRAB9ANPC1HPGDFFAR1 | |
| SCHEMBL3366087 | 0.89 | ALDH1A1 (0.66) | TSHRRAB9ANPC1HPGDFFAR1 | |
| SCHEMBL3366492 | 0.87 | TSHR (0.57) | TSHRMAPK1RAB9ANPC1HPGD | |
| SCHEMBL3367994 | 0.87 | HPGD (0.61) | TSHRMAPK1RAB9ANPC1HPGD | |
| SCHEMBL3366484 | 0.87 | TSHR (0.57) | TSHRMAPK1RAB9ANPC1HPGD | |
| SCHEMBL3368001 | 0.87 | HPGD (0.61) | TSHRMAPK1RAB9ANPC1HPGD | |
| SCHEMBL3366545 | 0.85 | NPC1 (0.61) | TSHRMAPK1RAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542969-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-03-03 | — | — | EP | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | claimed |
| EP-1542969-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | claimed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | claimed |
| WO-2004026827-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | claimed |
| EP-1542969-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-03-03 | — | — | EP | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7122562-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | IDING HANS | 2006-06-08 | — | — | US | disclosed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1542969-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004026827-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | TSHR 880/4885MAPK1 1645/4885RAB9A 3058/4885 |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | TSHR 3944/4885MAPK1 1455/4885RAB9A 1750/4885 |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | MAOA, MAOB, PNPO | TSHR 2304/4885MAPK1 982/4885RAB9A 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.